The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
Bavanthi Balakrishnar
No relevant relationships to disclose
Alexander M. Menzies
No relevant relationships to disclose
Sayed Sahanawaz Ali
No relevant relationships to disclose
Shang Heng Yeap
No relevant relationships to disclose
Bo Gao
No relevant relationships to disclose
Chris Liddle
No relevant relationships to disclose
Sally Coulter
No relevant relationships to disclose
Pamela Provan
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Rina Hui
No relevant relationships to disclose
Richard Kefford
No relevant relationships to disclose
Nicholas Wilcken
No relevant relationships to disclose
Rosemary L Balleine
No relevant relationships to disclose
Howard Gurney
No relevant relationships to disclose